kabutan

Ajinomoto Co., Inc.(2802) Summary

2802
TSE Prime
Ajinomoto Co., Inc.
3,442.0
JPY
+60.0
(+1.77%)
Jan 29, 1:37 pm JST
22.49
USD
Jan 28, 11:38 pm EST
Result
PTS
outside of trading hours
3,438.9
Jan 29, 1:37 pm JST
Summary Chart Historical News Financial Result
PER
27.6
PBR
4.64
Yield
1.39%
Margin Trading Ratio
0.93
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
3,387.0 JPY 22.12 USD
Previous Close Jan 28
3,382.0 JPY 22.15 USD
High Jan 29, 10:02 am
3,460.0 JPY 22.63 USD
Low Jan 29, 9:00 am
3,383.0 JPY 22.09 USD
Volume
2,581,600
Trading Value
8.86B JPY 0.06B USD
VWAP
3433.44 JPY 22.44 USD
Minimum Trading Value
344,200 JPY 2,249 USD
Market Cap
3.37T JPY 0.02T USD
Number of Trades
6,100
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
4,870
1-Year High Nov 10, 2025
20,284
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 123,900 3,031,100 24.46
Jan 16, 2026 111,300 2,739,100 24.61
Jan 9, 2026 115,900 2,823,300 24.36
Dec 26, 2025 122,000 2,528,300 20.72
Dec 19, 2025 132,100 2,520,400 19.08
Company Profile
Ajinomoto Co., Inc. is a leading comprehensive food company, ranking first in seasonings. The company has diversified into pharmaceuticals, animal feed, and other sectors, and is actively pursuing M&A opportunities.
Sector
Foods
Ajinomoto Co., Inc. is a comprehensive food manufacturer with a primary focus on seasonings, nutritional and processed foods, solution and ingredients, and frozen foods. The company also operates in non-food sectors, including pharmaceutical and food-grade amino acids, biopharmaceutical services (CDMO), and functional materials (such as electronic materials). With numerous subsidiaries both domestically and internationally, Ajinomoto conducts business on a global scale. The company has particularly strong business foundations in Southeast Asia and South America. In the seasoning business, Ajinomoto has local subsidiaries in Thailand, Indonesia, Vietnam, the Philippines, and Malaysia, among others. The frozen food business has also expanded into North America. Additionally, the company is focusing on strengthening its biopharmaceutical services business.